Evaxion announces extension to january 14, 2025, of plan to implement ads ratio change

Copenhagen, denmark, january 10, 2025 - evaxion biotech a/s (nasdaq: evax) (“evaxion”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, today announced that it is amending the effective date for its plans to change the ratio of its american depositary shares (“adss”) to its ordinary shares, dkk 1 nominal value (the “ads ratio”), from the current one (1) ads representing ten (10) ordinary share to a new ads ratio of one (1) ads representing fifty (50) ordinary shares (the “ads ratio change”).
EVAX Ratings Summary
Quant
EVAX Quant Ranking
Sector
Industry
Quant Rating
Quant Score